Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Bard succession plan

This article was originally published in The Gray Sheet

Executive Summary

Group President Timothy Ring's accession to chairman and CEO, effective upon William Longfield's retirement Aug. 7, is confirmed by the company Feb. 13. The move was anticipated last fall although the firm had insisted the choice was not yet final (1"The Gray Sheet" Oct. 21, 2002, In Brief). Ring, 45, joined the firm in 1992 as VP-human resources, became group VP-international in 1993, and assumed his current responsibilities in 1997, most recently supervising the firm's Vascular and Specialty Access businesses. Bard Group President John Weiland, 47, will become president and chief operating officer in August under the succession plan...
Advertisement

Related Content

Bard prepares to Ring in New Year
Advertisement
UsernamePublicRestriction

Register

MT017891

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel